Welcome to LookChem.com Sign In|Join Free
  • or
Benzamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

155778-26-0

Post Buying Request

155778-26-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

155778-26-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 155778-26-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,5,7,7 and 8 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 155778-26:
(8*1)+(7*5)+(6*5)+(5*7)+(4*7)+(3*8)+(2*2)+(1*6)=170
170 % 10 = 0
So 155778-26-0 is a valid CAS Registry Number.

155778-26-0Downstream Products

155778-26-0Relevant academic research and scientific papers

3-Amidoquinuclidine derivatives: Synthesis of compounds and inhibition of butyrylcholinesterase

Odzak, Renata,Tomic, Srdanka

, p. 90 - 98 (2006)

The synthesis of racemic and enantiomerically pure 3- butanamidoquinuclidines ((±)-Bu, (R)-Bu and (S)-Bu), (1-3) and 3-benzamidoquinuclidines ((±)-Bz, (R)-Bz, and (S)-Bz), (4-6) is described. The N-quaternary derivatives, N-benzyl-3-butanamidoquinuclidinium bromides ((±)-BnlBu, (R)-BnlBu and (S)-BnlBu), (7-9) and N-benzyl-3-benzamidoquinuclidinium bromides ((±)-BnlBz, (R)-BnlBz and (S)-BnlBz), (10-12) were subsequently synthesized. The interaction of the four enantiomerically pure quaternary derivatives with horse serum butyrylcholinesterase (BChE) was tested. All tested compounds inhibited the enzyme. The best inhibitior of the enzyme was (S)-BnlBz with a Ki = 3.7 μM. The inhibitor potency decreases in order (S)-BnlBz > (R)-BnlBz ? (R)-BnlBu > (S)-BnlBu.

HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS

-

Page/Page column 80, (2008/12/08)

This invention relates to M3 antagonists of formula (I) wherein R2, R4, R5, R6, W, V, A, D, X, t, u and v are as defined herein; pharmaceutical compositions containing them; methods for their preparation; and their use in the treatment of diseases where enhanced M3 receptor activation is implicated.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 155778-26-0